Literature DB >> 21735039

Second generation of fucose-based DC-SIGN ligands: affinity improvement and specificity versus Langerin.

Manuel Andreini1, Daniela Doknic, Ieva Sutkeviciute, José J Reina, Janxin Duan, Eric Chabrol, Michel Thepaut, Elisabetta Moroni, Fabio Doro, Laura Belvisi, Joerg Weiser, Javier Rojo, Franck Fieschi, Anna Bernardi.   

Abstract

DC-SIGN and Langerin are two C-type lectins involved in the initial steps of HIV infections: the former acts as a viral attachment factor and facilitates viral invasion of the immune system, the latter has a protective effect. Potential antiviral compounds targeted against DC-SIGN were synthesized using a common fucosylamide anchor. Their DC-SIGN affinity was tested by SPR and found to be similar to that of the natural ligand Lewis-X (Le(X)). The compounds were also found to be selective for DC-SIGN and to interact only weakly with Langerin. These molecules are potentially useful therapeutic tools against sexually transmitted HIV infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735039     DOI: 10.1039/c1ob05573a

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  8 in total

1.  The Human Glycoprotein Salivary Agglutinin Inhibits the Interaction of DC-SIGN and Langerin with Oral Micro-Organisms.

Authors:  Martine A Boks; Sabrina T G Gunput; Ilona Kosten; Susan Gibbs; Sandra J van Vliet; Antoon J M Ligtenberg; Yvette van Kooyk
Journal:  J Innate Immun       Date:  2016-04-16       Impact factor: 7.349

2.  Genetically encoded fragment-based discovery of glycopeptide ligands for carbohydrate-binding proteins.

Authors:  Simon Ng; Edith Lin; Pavel I Kitov; Katrina F Tjhung; Oksana O Gerlits; Lu Deng; Brian Kasper; Amika Sood; Beth M Paschal; Ping Zhang; Chang-Chun Ling; John S Klassen; Christopher J Noren; Lara K Mahal; Robert J Woods; Leighton Coates; Ratmir Derda
Journal:  J Am Chem Soc       Date:  2015-04-16       Impact factor: 15.419

3.  Systematic Dual Targeting of Dendritic Cell C-Type Lectin Receptor DC-SIGN and TLR7 Using a Trifunctional Mannosylated Antigen.

Authors:  Rui-Jun Eveline Li; Tim P Hogervorst; Silvia Achilli; Sven C Bruijns; Tim Arnoldus; Corinne Vivès; Chung C Wong; Michel Thépaut; Nico J Meeuwenoord; Hans van den Elst; Herman S Overkleeft; Gijs A van der Marel; Dmitri V Filippov; Sandra J van Vliet; Franck Fieschi; Jeroen D C Codée; Yvette van Kooyk
Journal:  Front Chem       Date:  2019-10-04       Impact factor: 5.221

Review 4.  Medicinal chemistry of the myeloid C-type lectin receptors Mincle, Langerin, and DC-SIGN.

Authors:  Jonathan Cramer
Journal:  RSC Med Chem       Date:  2021-09-16

5.  Virus-like glycodendrinanoparticles displaying quasi-equivalent nested polyvalency upon glycoprotein platforms potently block viral infection.

Authors:  Renato Ribeiro-Viana; Macarena Sánchez-Navarro; Joanna Luczkowiak; Julia R Koeppe; Rafael Delgado; Javier Rojo; Benjamin G Davis
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

6.  Glycosaminoglycans are interactants of Langerin: comparison with gp120 highlights an unexpected calcium-independent binding mode.

Authors:  Eric Chabrol; Alessandra Nurisso; Antoine Daina; Emilie Vassal-Stermann; Michel Thepaut; Eric Girard; Romain R Vivès; Franck Fieschi
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

7.  Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses.

Authors:  Dorian A Stolk; Aram de Haas; Jana Vree; Sanne Duinkerken; Joyce Lübbers; Rieneke van de Ven; Martino Ambrosini; Hakan Kalay; Sven Bruijns; Hans J van der Vliet; Tanja D de Gruijl; Yvette van Kooyk
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

Review 8.  Molecular Recognition in C-Type Lectins: The Cases of DC-SIGN, Langerin, MGL, and L-Sectin.

Authors:  Pablo Valverde; J Daniel Martínez; F Javier Cañada; Ana Ardá; Jesús Jiménez-Barbero
Journal:  Chembiochem       Date:  2020-07-02       Impact factor: 3.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.